Skip to main content
. 2019 Apr 1;5(2):e321. doi: 10.1212/NXG.0000000000000321

Figure 4. Reduction of POPDC1 and PODPC2 at the sarcolemma in muscle of patients harboring homozygous mutations in BVES.

Figure 4

(A and B) Representative muscle sections of patients and controls immunostained for POPDC1 and POPDC2, respectively, and α-sarcoglycan (SGCA) as sarcolemmal marker. All images were acquired with identical settings and are displayed in the figure with identical intensity scaling for each channel. Scale bar = 50 μm. (C and D) Fluorescence intensities measured at the sarcolemma (n = 30 sarcolemmal segments at random positions on the section). AU = arbitrary unit.